Thank you, Madam Chair.
Thanks to our witnesses for coming here today.
Dr. Gagnon, can I start with you, please? I was flipping through the deck you provided us, which is very much appreciated. On page 25, there's something that you term “A Modest Proposal”, which talks about patent restoration and extended data exclusivity. Is that to suggest that the 1987 deal that was implicit in the Patented Medicines Price Review Board makes some sense if enforced and administered properly?